Lexeo Therapeutics, Inc. (LXEO) Dividend History

Lexeo Therapeutics, Inc. is a biotechnology company focused on developing therapies for rare neurodegenerative diseases. The company leverages gene therapy and other advanced modalities to address unmet medical needs, aiming to improve quality of life for patients with limited treatment options.

345 Park Avenue South, New York, NY, 10010
Phone: (212) 547-9879
Website: https://www.lexeotx.com

Dividend History

Lexeo Therapeutics, Inc. currently does not pay dividends

Company News

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Lexeo Therapeutics announces positive interim data for its gene therapy candidate LX2006 in treating Friedreich ataxia cardiomyopathy, with participants showing clinically significant improvements in cardiac biomarkers and increased frataxin expression. The company plans to initiate a registrational study by early 2026.

GlobeNewswire Inc.
2 Stocks Riding the Biotech Surge With Major Catalysts Ahead

The biotechnology sector has experienced significant volatility, with Tonix Pharmaceuticals and Lexeo Therapeutics seeing major stock price surges. These surges were driven by positive regulatory updates and financial results, respectively, indicating potential long-term value for these companies.

Investing.com

Featured Companies: TNXP
What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock

Lexeo Therapeutics, Inc. (LXEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research
Wall Street Breakfast: The Week Ahead

This article discusses the upcoming events in the financial world, including the Federal Reserve meeting, corporate earnings, IPOs, and investor events.

Seeking Alpha

Featured Companies: AAPL AMD AMGN AMZN ANVS ATGL BKNG CHGG COP COTY CTNM CVS CZR DASH DD DPZ EBAY FTNT H HSY KHC KO KOPN LLY LMND LNG MA MAMO MAR MCD MDB MDLZ MED MET MGA MGM MSTR NXPI OCUL ON PAA PFE PRTS PYPL QCOM RIOT SBUX SGMT SMCI SMR SRRK TEAM TSLA
RBC Capital Maintains Outperform Rating for Lexeo Therapeutics: Here's What You Need To Know

RBC Capital has decided to maintain its Outperform rating of Lexeo Therapeutics (NASDAQ:LXEO) and raise its price target from $22.00 to $24.00. Shares of Lexeo Therapeutics are trading up 7.11% over the last 24 hours, at $15.52 per share. A move to $24.00 would account for a 54.64% increase from the current share price. About Lexeo Therapeutics Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. ...Full story available on Benzinga.com

Benzinga

Page data last updated 07/23/2025 10:03:24 UTC